标签之外的JAK抑制剂:皮肤病学新兴应用
Giulio Foggi1,2, Francesco D'Oria1,2, Costanza Falcidia1,2
1Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.
Medicina (Kaunas, Lithuania)
|January 28, 2026
概括
口服的Janus激酶抑制剂 (JAK) 在非标签性皮肤病症中表现出广泛的疗效. 这些JAK抑制剂在现实环境中提供快速反应,持续的疾病控制和有利的安全概况.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 口服的Janus激酶抑制剂 (JAK) 已被批准用于阿托皮性皮肤炎和白发性脱发症.
- 它们的免疫调节作用导致对耐火性炎症性皮肤疾病的非标签使用增加.
研究的目的:
- 审查已发表的关于口服JAK抑制剂非标签性皮肤学使用的文献.
- 在现实环境中总结临床结果,安全性和治疗持续时间.
主要方法:
- 在PubMed上搜索关于巴里西提尼布,阿布罗西提尼布,阿巴西提尼布和瑞特利西提尼布的病例报告和系列.
- 数据提取包括治疗细节,结果和不良事件.
主要成果:
- 分析了136篇文章,重点是abrocitinib,upadacitinib和baricitinib. 在这些文章中,我们分析了136篇文章,重点是abrocitinib,upadacitinib和baricitinib.
- 在各种皮肤病症中观察到一致的临床疗效,反应迅速.
- 良好的耐受性,主要是轻微和短暂的不良事件.
结论:
- 口服JAK抑制剂在皮肤病学中显示出显著的非标签治疗潜力.
- 迅速发病,持续反应和良好的安全性支持在选定的患者中使用它们.
- 在剂量调整或中止后,经常观察到缓解的维持.
关键词:
雅克-抑制剂的使用亚布罗西提尼布是什么意思巴里西提尼布 (baricitinib) 是一种药物.里特利西提尼布 (ritlecitinib) 是一种药物.在此之前,upadacitinib 已经在使用中.更多相关视频
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
15.2K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.8K
相关概念视频
Applications of GIS: Disaster Management and Emergency Response
503
Geographic Information System (GIS) technology is essential for risk identification, action prioritization, and resource optimization in critical situations like flooding and earthquakes. By integrating spatial and demographic data, GIS provides a comprehensive framework for emergency response.GIS integrates data layers, like rainfall intensity, topography, elevation profiles, and river levels, to model high-risk flood zones. These layers assess areas susceptible to flooding based on their...
503
Emerging Adulthood
663
Jeffrey Arnett's concept of emerging adulthood offers a framework to understand the unique developmental stage between adolescence and full-fledged adulthood, generally from ages 18 to 25. This period is marked by extensive exploration and shifts in identity, relationships, and career choices, a process known in psychology as role experimentation. Emerging adulthood reflects the evolving cultural expectations surrounding adulthood and the dynamic process of personal transformation during...
663
The JAK-STAT Signaling Pathway
12.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
12.4K
Eukaryotic Transcription Inhibitors
11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Introduction Cardiac Emergencies
327
Cardiac emergencies are critical situations involving the heart that require immediate medical intervention to prevent severe complications or death. These emergencies often arise from underlying heart conditions that impair the heart's ability to function correctly.Types of Cardiac EmergenciesThe most common types of cardiac emergencies include Acute Coronary Syndrome (ACS), myocardial infarction (MI), cardiac arrest, and heart failure.Acute Coronary Syndrome (ACS)Acute Coronary Syndrome (ACS)...
327
Dipeptidyl Peptidase 4 Inhibitors
644
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
644
